SBRT improves PFS in addition to antiandrogen therapy. The question is, with oligomets, do we need systemic therapy in all patients? Or will SBRT be sufficient?
I encourage our FCS radiation oncologists to provide their input on this study, as well.
This is another possibility for maintenance therapy. It will require further study.
Good review of high-risk patients, showing that prophylactic high dose MTX did not have lower risk of CNS disease.
There have been studies showing decreased recurrence in women who underwent curative breast surgeries (walking and yoga). This study assesses if it will affect the intensity of chemotherapy delivered. Although it did not affect it, women who underwent the program had better pathologic complete response (pCR), we need more studies to assess role of nutrition and exercise in treating cancer as we develop a wholesome approach to treat our patients, something we may be able to do in our practice.
Although Osimertinib in another trial (article from a previous month) had also impressive response first-line osimertinib initiation of 25 days. In total, 136 previously untreated brain metastases were tracked from baseline. Overall, 105 lesions (77.2%) had complete response and 31 had partial response reflecting best objective response of 100%.
Lazertinib, third generation EGFR inhibitor, has good activity in patients with brain mets promising…
A different PD-1 inhibitor improves survival in patients with unresectable gastric of GEJ tumors, CPS >5, they also had maintenance capecitabine. Confirming role for maintenance immunotherapy.
We get this often in hospital consults, it seems transfusing when hemoglobin is above 7 did not significantly help. The debate continues. What are your thoughts? I’m a believer in restrictive transfusion (using clinical judgment rather than specific hemoglobin value).
Sorafenib did not help in newly diagnosed AML (with FLT-ITD) patients as maintenance therapy. MRD testing can also predict survival outcome.
A small number of patients in this study, but it is an interesting test to predict who can be off therapy in CML. Patients who are high risk probably should to be taken off therapy, but this gives us something to build on.
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
